Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nope. But thanks for ur concern. I’ll hold my 400k investment straight into the dirt with these dirtbags. But good luck to you. Just trying to give you a heads up, not bash a stock. I should care less about other investors but thought a public service announcement was in order.
ok then take care. i assume you have gone by now. RSPI
This company is a piece of shit. They’ve been taking aim and talking at conferences for 25 years. It validates their paychecks. Their patents are near expiration and their pipeline is dead. They had their chance and blew the ampakines shot on goal over a decade ago. Good luck but don’t bank on a future other than flipping a few pennies here. Just google CX-717. That was their prize pony. It’s got more dust on it than king tuts tomb.
The CEO is British. I’ve been in RSPI for a long time. I strongly believe this will soon capitalize on its long anticipated potential.
I know RSPI has international ties. They were speaking at some sort of cannabinoid conference in the UK, I think late last year.
I see. Well, it would be nice if it were a hero.
RSPI is about to explode to the upside IMO guys! watchin! RSPI
Everyone is just busy with PLTR. Good to see this one moving in right direction though. This one is going to be a hero or a zero.
Hello, is this thing on? Is there anybody out there?
How many shares do people own? I'm wondering how invested people are here.
I've watched this company for about a year or so now. I was waiting for a good time to jump in, I pulled the trigger yesterday.
Biotech is super hot now and there aren't too many legitimate plays under a dime.
The OTC market is super hot and this one has yet to run. RSPI was at $1.49 post-RS last year, the RS is complete now. I think our turn is very soon.
This one trades in a different way than most, probably because of the very small O/S. But, I own a ton of this.
.04 area should be bottom for now, we’ll see...
Possible .10+ this week $$RSPI
Possible .10+ this week $$RSPI
The R/S should start to pay off here , money coming
This is going to move big time. The catalyst for this is amazing. The SS makes it even more sexier.
BOL!
Someone accumulating big time. Level 2 bid for 928,000 shares. 800k purchase last week. Get ready for take-off!
Up 20% not too shabby $RSPI
Looking into this... will have to check l2 and do some more dd on this before anything
One solid PR will be an explosive move up from here. Coming IMO...
Incredible 880,000 buy at the close. Someone bought about 1.3% of the company with that trade. Unbelievable. Makes you think someone knows something. Will see how crazy this gets tomorrow.
yes thanx. its a clear buy here, and ill be averaging down. RSPI
Seems a little busier than normal. Lets hope some news is coming.
Good to see you here! $RSPI
guys got a starter here! THose who know and follow me know what happens once I start getting involved! were good here! RSPI
Could be a really good spot to buy here in the mid .03’s
Good Morning $RSPI ! Time to add some!
$RSPI #OTCQB RespireRx Pharmaceuticals Inc. (RSPI: OTCQB) | Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI
Copyright 2021 – OTC Markets Group Inc.
It will move much faster with this SS ! If they announce partnership $ RSPI will go Crazy!
I've been with this one for a couple of years, and I've been through two R/S. But I have averaged down, and now I am comfortable with my position.
Have to admit: always staying away from the RS ! But this one nicely done with only 10-1 and we are back on the OTCQB + reducing convertibles to almost nothing! Market Cap Crazy low with so much in the pipeline. I see gap on the chart around $.80 c Which bring MC to $60 mill - not crazy in my book! Adding $RSPI
Yep, finally primed for success.
$RSPI Market Cap only $2.5 mill with Float only 47 mill and Two Phase 2 clinical trials!
“February 5, 2021, the closing price of our Common Stock was $0.037 per share and there were 75,646,039 shares of our Common Stock outstanding, on a post-Reverse Split basis. Due to the Reverse Split, 115,000,000 shares noted above and in the Final Prospectus now relate to 11,500,000 post-Reverse Split shares.” $RSPI
Have fun with that.
$RSPI shares will just get more and more expensive!
RespireRx is developing a pipeline of new drug products based on our broad patent portfolios across two distinct drug platforms:
(i)
ResolutionRx, our pharmaceutical cannabinoids platform including dronabinol (a synthetic form of ?9-tetrahydrocannabinol (“?9-THC”)), which acts upon the nervous system’s endogenous cannabinoid receptors, and
(ii)
EndeavourRx, our neuromodulators platform is made up of two programs: (a) our ampakines program, including proprietary compounds that are positive allosteric modulators (“PAMs”) of AMPA-type glutamate receptors to promote neuronal function and (b) our GABAkines program, including proprietary compounds that are PAMs of GABAA receptors,
Buying $RSPI ! So much in the pipeline! Easy 1000% from here!
I was wondering why everything was out of wack...couldn’t trade it
Looks like we lost the "D" today. I feel so naked.
It's trying to climb out of its hole...
This one’s been at the bottom of my watchlist for a long time, back in small, could be news and big moves ahead, we’ll see...
We are slowly climbing the wall of pain. But, IMO, we will get to the top.
I like the moves here today! Hope we see more Green Days
Going nowhere quickly. No Biotech Conference news.
Followers
|
352
|
Posters
|
|
Posts (Today)
|
233
|
Posts (Total)
|
49293
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators oldstocks DTGoody powerbattles fly_fisherman archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
8-K | 10/02/2023 | 09/26/2023 | PDFRTFHTMLXLS |
10-Q | 08/21/2023 | 06/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 08/14/2023 | 06/30/2023 | PDFRTFHTML |
8-K | 08/09/2023 | 08/03/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |